Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment.
Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Buee L, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O; BALTAZAR study group. Lehmann S, et al. Among authors: paquet c. J Neurol Neurosurg Psychiatry. 2024 Apr 24:jnnp-2024-333467. doi: 10.1136/jnnp-2024-333467. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38658136 Free article.
Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, Lehmann S, Paquet C, Amar-Bouaziz E, Magnin E, Miguet-Alfonsi C, Delbeuck X, Lavaux T, Anthony P, Philippi N, Blanc F; ePLM network and collaborators. Bousiges O, et al. Among authors: paquet c. J Neurol Neurosurg Psychiatry. 2018 May;89(5):467-475. doi: 10.1136/jnnp-2017-316385. Epub 2018 Jan 10. J Neurol Neurosurg Psychiatry. 2018. PMID: 29321140
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Tréluyer JM, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert PH, Godefroy O, Dantoine T, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A; BALTAZAR study group. Hanon O, et al. Alzheimers Dement. 2018 Jul;14(7):858-868. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17. Alzheimers Dement. 2018. PMID: 29458036 Free article.
What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France.
Cognat E, Mouton Liger F, Troussière AC, Wallon D, Dumurgier J, Magnin E, Duron E, Gabelle A, Croisile B, de la Sayette V, Jager A, Blanc F, Bouaziz-Amar E, Miguet-Alfonsi C, Quillard M, Schraen S, Philippi N, Beaufils E, Pasquier F, Hannequin D, Robert P, Hugon J, Paquet C; ePLM network. Cognat E, et al. Among authors: paquet c. BMJ Open. 2019 May 30;9(5):e026380. doi: 10.1136/bmjopen-2018-026380. BMJ Open. 2019. PMID: 31152032 Free PMC article.
Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study.
Mouton-Liger F, Wallon D, Troussière AC, Yatimi R, Dumurgier J, Magnin E, de la Sayette V, Duron E, Philippi N, Beaufils E, Gabelle A, Croisile B, Robert P, Pasquier F, Hannequin D, Hugon J, Paquet C. Mouton-Liger F, et al. Among authors: paquet c. J Neurol. 2014 Jan;261(1):144-51. doi: 10.1007/s00415-013-7160-3. Epub 2013 Oct 27. J Neurol. 2014. PMID: 24162039
466 results